Drugs / Ceftolozane/tazobactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06035055 | Oct 2023 | Pseudomonas aeruginosa infectious disease, bronchiectasis, burkholderia infectious disease, cystic fibrosis | Sunshine Coast Hospital and Health Service | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ceftolozane/tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06035055 ↗ |
| Route | Intravenous | “IV infusion” NCT06035055 ↗ |